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PATHOGENESIS AND TREATMENT OF NEUROBLASTOMA 
LEIDY ORTIZ 
ABSTRACT 
 Neuroblastoma (NB) is the most common extracranial solid tumor that 
occurs in children. NB is highly metastatic and varies in risk level according to 
tumor histology and genetic characteristics. The amplification of the MYCN 
oncogene is one of the key factors that promotes the development of tumors and 
is associated with poor prognosis. Mutations in the tyrosine kinase ALK gene 
have also been linked to tumorigenesis, especially in familial neuroblastoma. 
Other genetic mutations that have been identified include ATRX, PTPN11, 
ARID1A, ARID1B, and genes involved in neuritogenesis. Genetic aberrations like 
chromothripsis, the loss of chromosome segments 1p and 11q, as well as the 
gain of segment 17q may also be linked to the development of NB. Treatment for 
this disease varies according to the patient’s risk profile but may include surgery, 
high dose chemotherapy with or without bone marrow transplantation, and 
radiation. Several immunotherapy drugs, as well as drugs that target the disease 
pathway, are currently in development with the goal of improving treatment, 
survival rates, and quality of life. This review will discuss the molecular and 
genetic factors that drive neuroblastoma. It will also discuss the current 
treatments and survival rates of the disease as well as recent and ongoing 
treatment research.  
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INTRODUCTION 
 
Neuroblastoma is one of the most prevalent solid tumors in children and 
accounts for 15% of pediatric cancer deaths in the United States (Kim and 
Chung)1. The disease usually affects children under the age of 5 and is most 
common in children under the age of 1, though teens and adults can also be 
affected. Survival rates for NB vary according to several risk factors and age at 
the time of diagnosis. Overall survival for infants under 18 months of age is 88%, 
49% in children between 18 months and 12 years of age, and only 12% in 
adolescents and adults.2,3,4 Currently, there is no standardized screening for 
neuroblastoma. Tumors may often form before birth and may not be found until 
they have progressed to a point in which they cause symptoms. The majority of 
NB cases occur sporadically, but according to the National Cancer Institute (NCI) 
1% to 2% of cases are genetic or familial in nature.5 Genetic cases follow an 
autosomal dominant inheritance pattern with incomplete penetrance6, meaning 
that not everyone who carries the mutation will develop the disease. Due to the 
rarity of familial neuroblastoma, this review will mainly focus on the pathogenesis 
and treatment of sporadic cases.  
NB tumors typically appear in the abdominal region, but they can emerge 
on any axial level of the sympathetic chain as seen on figure 1. Approximately 
half of these abdominal tumors manifest in the adrenal glands.7 Regardless of 
their location on the body, tumor cells seemingly have a common embryological 
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origin, as they are derived from neural crest cells. During embryogenesis, neural 
crest cells migrate towards different areas of the body in order to give rise to 
various cells and structures, including the adrenal glands, melanocytes, facial 
bone, and the nervous system. The widespread migration of neural crest cells 
and their association with the onset of neuroblastoma may explain why tumors 
have the potential to appear on several axial levels of the torso.  
NB is largely heterogeneous, as cases can have a variety of clinical 
outcomes. Lower risk tumors can regress or differentiate spontaneously into a 
benign ganglioneuroma.8 Some moderate and high-risk tumors may respond to 
treatment, while others may become resistant and ultimately lead to death. 
Several genetic mutations and alterations that play a role in NB pathogenesis 
have been identified. Some of these factors include, but are not limited to, the 
amplification of the MYCN oncogene, mutations in a tyrosine kinase receptor 
known as anaplastic lymphoma kinase (ALK), genetic aberrations involving the 
loss or gain of alleles, chromothripsis, and neuritogenesis genes. Among these, 
studies have demonstrated that MYCN is consistently the most important factor 
when determining risk level, as MYCN amplified tumors are especially 
aggressive.9 Activating ALK mutations have proven to be the main cause of 
familial cases of neuroblastoma, although mutations in this gene can also be 
found in sporadic NB. 6  
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Figure 1.	  The Sympathetic trunk. Neuroblastoma can arise along any level of 
the sympathetic chain as shown. Most neuroblastomas arise in the abdominal 
sympathetic nerve ganglia, half of these are associated with the adrenal glands. 
Image taken from the National Cancer Institute’s Physician Data Query on 
Neuroblastoma Treatment. 5 
 
 
A major focus for researchers is the regression and spontaneous differentiation 
of NB, as it may lead to greater understanding of the disease and the 
development of possible therapies. TrkA expression has been linked to the 
tumor’s ability to spontaneously regress or progress. Tumors expressing 
TrkA/NTRK1 show a favorable prognosis.10,11 In contrast, tumors that express 
TrkB/NTRK2 or brain-derived neurotrophic factor (BDNF) are associated with 
unfavorable prognosis.12  
	  4 
The current treatment options focus on three approaches to treating 
tumors. These include surgical removal of the tumor, chemotherapy or radiation, 
and a combination of these therapies.5 Like other types of cancers, NB can 
metastasize and become challenging to treat by spreading to the liver, lungs, 
skin, and bone.13 Current knowledge on prognostic factors, like ALK and MYCN 
amplification, provides clues for potential pathways that can be exploited in order 
to find new and improved treatment for patients. Several clinical trials are 
currently being held with the goal of finding an effective targeted therapy for the 
disease.  
    
     SYMPTOMS AND STAGING 
 
Common Symptoms 
 Neuroblastoma tumors are often present at birth and continue to grow in 
childhood. Nearly 20% of cancers are diagnosed within the first year of life and 
can be detected in the womb.14 Tumors most commonly manifest in the 
abdominal area, but they can appear along any region of the sympathetic trunk, 
including the neck, hip and facial region.15 Affected children may exhibit weight 
loss, diarrhea, fever, as well as increased urination or trouble breathing as a 
consequence of tumor compression.16 The cancer most commonly metastasizes 
to the skin, liver, and bones (especially the orbital bones).17 Metastasis to the 
orbital bones causes periorbital ecchymosis, more commonly known as “raccoon 
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eyes” (figure 2).17 Some patients with neuroblastoma may also develop bluish 
lesions on the skin known as “blueberry muffin skin lesions.”16 
 
 
Figure 2. Periorbital Metastasis and Raccoon Eyes. Depiction of bilateral 
periorbital ecchymosis or “Raccoon Eyes” (A) and an MRI image (B) 
demonstrating metastasis of neuroblastoma to the skull. The tumor in (B) is 
associated with the zygomatic, sphenoid, and temporal bones. Image taken from 
Timmerman.18   
 
Detection and Staging Methods 
 Routine screening for neuroblastoma in all children is not recommended, 
as it may lead to over-diagnosis and unnecessary treatment of tumors that would 
oftentimes mature and resolve on their own.19 Over-diagnosis and treatment can 
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lead to further complications and co-morbidities. When infants are suspected of 
having NB, urine is collected and tested for vanillylmandelic acid and 
homovanillic acid levels19. Both of these substances are metabolites of 
norepinephrine, epinephrine, and dopamine, which can be secreted by 
neuroblastoma tumors.20 The urine screening method has a diagnostic sensitivity 
of 82%.21 
 Once NB is confirmed, it is essential to perform appropriate staging to 
understand the extent of disease. NB is staged using the International 
Neuroblastoma Staging System (INSS) that was originally proposed in 1988 and 
has been modified based on new findings as seen on Table 1.22 The INSS 
focuses on the primary tumor and the extent to which the disease has spread. 
About 75% of children diagnosed after the age of one are in stages 3 or 4, while 
infants younger than 1 year tend to be at the lower stages of 1,2, and 4s.15 
Tumors that are categorized as stage 2B have been found to be the most 
aggressive.23 NB may regress completely in infants, especially those in the 4s 
stage, even without the need of intense therapy.23 
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Table 1. International Neuroblastoma Staging System. Risk increases with 
stage progression, excluding stage 4S which may regress spontaneously. Taken 
from Monclair et al.22 
 
 
Stage Description 
1 Tumor is localized to the area of origin and can be completely 
removed through surgery. Bilateral lymph nodes negative 
microscopically.  
2A Localized tumor and incomplete gross excision. Bilateral lymph nodes 
negative microscopically.  
2B Localized tumor with or without complete excision. Ipsilateral, non-
adherent lymph nodes are positive, contralateral lymph nodes are 
negative.  
3 Unresectable tumor infiltrates across midline, with or without proximal 
lymph node involvement; or localized tumor with contralateral regional 
lymph node positive.  
4 Tumor spread to distant lymph nodes, skin, bone marrow, bone, liver, 
or other organs.  
4S Localized primary tumor as previously described in 1, 2A, 2B. 
Metastasis only to skin, liver, and/or bone marrow. Stage is limited to 
infants younger than 1 year.  
 
 
 It is equally important to determine the stage of the disease on a cellular 
level. Shimada et al proposed an international Neuroblastoma Pathology 
Classification based on age at the time of diagnosis, degree of cellular 
differentiation, nuclear morphology, and the organization of stromal tissue in the 
primary tumor.24 Histological studies have noted that NB is associated with two 
major types of cells: one type is the meroblastic cells of neural crest lineage and 
the other consists of non-neuronal cells, including Schwann cells.25 Schwann 
cells are part of the peripheral nervous system and are a type of support cell that 
produce the myelin sheaths that cover neuronal axons. When noting the stromal 
conditions of the samples, Shimada et al assigned them to two different 
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categories, stroma-poor and stroma-rich groups. Stroma-poor cases were 
characterized as being composed of mostly neuroblastic cells, while stroma-rich 
cases were those that contained higher amounts of Schwann cells or other 
supporting elements.   
 A level of differentiation was also assigned to each category. Stroma-poor 
cases were graded as being either “non-differentiated” or “differentiating”. The 
“non-differentiated” label indicates that less than 5% of the neuroblasts were 
differentiating. The “differentiating” label indicates that at least 5% of the cells 
were differentiated or of higher maturity. Stroma-rich cases were graded to be 
either “well differentiated” or “intermixed”. Stroma-rich tumors were considered to 
be ganglioneuroblastoma rather than the classical neuroblastoma, as they were 
typically composed of more differentiated cells, whereas the stroma-poor groups 
were identified as classical neuroblastoma or diffuse ganglioneuroblastoma. A 
second study performed by Shimada et al confirmed that the younger the child at 
the onset of disease and the more differentiated the tumor cells, the more 
favorable the prognosis.26 
 A comprehensive risk assessment is typically used to estimate the survival 
rate for patients. An international neuroblastoma risk group (INRG) classification 
system was designed as a way to establish a consensus on risk stratification.2 
The INRG includes four stages, L1, L2, M, and MS. L1 classification is assigned 
to localized tumors that do not involve vital structures and are confined to one 
compartment of the body. L2 classification is given to loco-regional tumors with 
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one or more image defined risk factor. M is defined by distant metastatic disease 
except for MS. Finally, MS is defined by metastatic disease in a child under 18 
months of age with metastasis limited to skin, liver, and/or bone marrow. A 
summary of classification stages and relative histologic categories, ploidy, MYCN 
status, and risk level is shown in table 2.  
 
Table 2. Pre-treatment Risk Analysis of Neuroblastoma. Risk is based on 
stage, age of patient at diagnosis, histologic classification, tumor differentiation, 
MYCN amplification, and chromosomal aberrations (taken from Cohn et al).2  
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ORIGIN OF NEUROBLASTOMA 
 
Neuroblastoma may commonly affect the adrenal glands. The adrenal 
glands are located superiorly to the kidneys and are comprised of three layers: 
the capsule, the cortex, and the medulla as seen on figure 3. The medulla 
houses chromaffin cells with the ability to produce the stress hormones 
epinephrine, norepinephrine, and dopamine when stimulated by sympathetic 
neurons. Once released, the hormones cause the mobilization of glucose stores 
and increase both heart rate and blood pressure.  
 
Figure 3.  Layers of the Adrenal Gland. Layers include the adrenal capsule, 
cortex, and medulla. Many neuroblastomas are associated with chromaffin cells 
of the adrenal medulla. Taken from Junqueira’s Basic Histology by Mescher.27  
 
Neuroblastoma has been shown to affect differentiating chromaffin cells, 
which are of neural crest origin. Cells in the adrenal gland cortex are typically not 
involved in NB pathogenesis and are not derived from neural crest cells. It is, 
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therefore, important to understand embryogenesis and the development of neural 
crest cells in order to decipher the pathogenesis of NB. 
 The first four weeks of embryogenesis involve the formation of three 
functional germ layers that will eventually give rise to the embryo’s skin, nervous 
system, and organs. These layers are the ectoderm, mesoderm, and endoderm. 
The adrenal medulla is formed from the ectoderm layer while the adrenal cortex 
is derived from the mesoderm. Both the mesoderm and endoderm play a major 
role in the development of muscles, organs, and the epithelium of the gut and 
respiratory systems. The ectoderm layer will give rise to the nervous system and 
the skin. Some cells of the ectoderm layer will differentiate to form a thickened 
area known as the neural plate. The neural plate, which eventually gives rise to 
the central nervous system, folds in to form the neural tube. The crest of the fold 
is commonly known as the neural crest and once the folding process is over, the 
cells in this location will disassociate to form neural crest cells. The neural tube 
then sinks below the ectoderm and the ectoderm fuses over it (figure 4) to later 
form the skin.  
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Figure 4. Formation of Neural Tube from Ectoderm. A portion of ectoderm 
thickens (A) and folds (B,C) to form the neural tube (D). Neural crest cells, which 
originate from the crest of the fold, detach once the neural tube closes. Figure 
taken from Schoenwolf et al.28  
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 As the embryo continues to develop, neural crest cells delaminate from the 
neural tube and migrate from the ectoderm layer to the mesenchyme, a process 
known as epithelial-mesenchymal transition (EMT). Neural crest cells, which 
have migratory and pluripotent capabilities, travel to other areas of the embryo to 
give rise to a variety of structures. They have the potential to differentiate into 
peripheral neurons, smooth muscle cells, chondroblasts, osteoblasts, and 
chromaffin cells depending on the axial level of the body to which they migrate 
to.13 The process of induction and migration of neural crest cells is regulated by a 
complex network of transcription factors, also known as neural crest specifiers 
(i.e MYCN, c-myc, Id2, PHOX2, Sox9, Sox10, Twist, and Slug/Snail).28 The 
signaling molecule bone morphogenic protein and the transmembrane receptor 
NOTCH appear to play a role in the regulation of these transcription factors .29 In 
addition to allowing the cell to migrate, these specifiers can also assign a 
particular neural crest lineage and control differentiation.30 Alterations in the 
functioning of neural crest specifiers may be involved in the upregulation of 
proliferation and the suppression of differentiation, leading to tumorigenesis and 
malignancy.28 It is likely that the neoplastic event that causes neural crest cells to 
become carcinogenic occurs sometime after EMT but before complete 
differentiation.31 Interestingly, neuroblastoma can develop from neural crest cells 
in the sympathoadrenal lineage and not from other lineages.32 
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DISEASE MECHANISMS 
 
 Understanding the mechanisms by which neuroblastoma develops is 
incredibly important, as it can help scientists develop therapies that specifically 
target the disease pathway. Although these mechanisms have not been 
completely deciphered, some of the key players of this process have been 
identified and involve several functional and genetic alterations.  
 
Tyrosine Kinase Receptors  
 ALK belongs to the tyrosine kinase receptor family, which includes other 
members like the epidermal growth factor receptor (EGFR/HER-1) that is 
associated with breast cancer. These receptors play a vital role in the cancerous 
transformation of the cell, as they involve the regulation of cellular growth, 
proliferation, and differentiation. ALK mutations have been found to be the main 
cause of familial neuroblastoma,33 although activating somatic mutations have 
also been found in sporadic NB.34  A study by George et al, found that some 
neuroblastomas exhibited ALK amplification while others had mutated ALK 
kinase domains.34 The study also found 5 previously unidentified ALK mutations 
of which two were germline mutations and two were somatic. The most common 
mutation appeared to be F1174L, which involves the substitution of an amino 
acid at position 1174 from a phenylalanine (F) to a leucine (L). This ALK mutation 
is also found in some types of lung cancer and has been thought to cause an 
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acquired resistance to Crizotinib, a drug that functions as a tyrosine kinase 
inhibitor.35 Aside from F1174L, approximately two dozen ALK mutations have 
been identified in total.36  
 ALK contains 1620 amino acids and like other tyrosine kinase receptors, it 
has an intracellular catalytic domain, a transmembrane domain, and an 
extracellular ligand-binding domain; ligands include pleiotrophin and midkine , 2 
homologous growth factors that are expressed in the embryo but decrease at 
birth.37 After ligands bind to the extracellular domain, the receptors dimerize and 
cross phosphorylate. Mitogen- activated protein kinase (MAPK), 
phosphoinositide 3-kinase (PI3K), and phosphoinositide phospholipase Cγ 
(PLCγ) pathways can be activated by phosphorylated ALK as seen on figure 5. 
These pathways lead to cellular proliferation, migration, differentiation, and the 
activation of survival mechanisms.38   
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Figure 5.  Proposed ALK and WNT Mechanisms. ALK can activate RAS, PI3K, 
and PLCγ pathways to promote tumorigenesis. WNT acts through the canonical, 
β-catenin dependent pathway to promote tumorigenesis. Both pathways may 
interact with MYCN downstream. Figure adapted from findings by Holla et al and 
Johnsen et al.38,39  
 
PI3K is a protein kinase that, in its inactive mode, has an adapter protein 
bound to its regulatory subunit. Once activated by ALK, PI3K will convert 
phosphatidylinositol (3,4)-bisphosphate (PIP2), a minor phospholipid component 
of the cellular membrane, to phosphatidylinositol (3,4,5)-triphosphate (PIP3).40 An 
increase in the concentration of PIP3 will activate AKT via the removal of a 
regulatory domain that blocks the AKT kinase domain. AKT will then 
phosphorylate and activate a protein known as mammalian target of rapamycin 
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complex 1 (mTORC1), leading to an increase in proliferation and protein 
synthesis through its actions on translational factors and ribosomal kinases.41  
In another pathway, activated ALK can subsequently lead to the activation 
of PLCγ. PLCγ can interact with PIP2, hydrolyzing it into inositol 1,4,5-
triphosphate (IP3) and 1,2-diacylglycerol (DAG). IP3 increases the concentration 
of free Ca2+ in the cytosol and activates protein kinase C (PKC), which plays a 
role in cellular proliferation and differentiation.42 The role of PKC in the 
progression of neuroblastoma has been confirmed in in-vitro studies where the 
addition of PKC inhibitors such as H7 and Calphostin C resulted in decreased 
proliferation of neuroblastoma cells.43  
 In the MAPK pathway, adaptor protein Grb2 binds to the phosphotyrosine 
tail of the receptor and to the guanine nucleotide exchange factor (GEF) SOS, 
which then activates a protein known as RAS by exchanging guanosine 
diphosphate (GDP) to guanosine triphosphate (GTP).44 Activated RAS will recruit 
RAF, a serine protein kinase, to the cellular membrane. RAF can then activate 
protein kinase MEK, and MEK can activate another protein kinase, ERK. ERK 
acts on transcription factors in the nucleus to upregulate proliferation.44 The 
MAPK signaling cascade in a normal cell is terminated and regulated in several 
ways. One of these is the spontaneous hydrolysis of GTP to GDP which will 
deactivate RAS. Other ways include the internalization of the ALK receptor and 
the deactivation of components by phosphatases in the cell. There has been 
evidence of RAS-MAPK activation in neuroblastoma tumor progression.45 In fact, 
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molecular studies have found that Neuroblastoma RAS (NRAS) is significantly 
mutated in a small number of high risk patients.46 Increased RAS-MAPK 
activation increases the expression of MAPK feedback inhibitors like dual 
specificity phosphatases (DUSPs) and sprouty proteins (SPRYs).47  
 There are several other tyrosine kinase receptors that have been linked to 
NB, specifically TrkA, TrkB, and TrkC. Expression of TrkA, which is activated by 
the ligand nerve growth factor (NGF), is associated with better prognosis and is 
inversely correlated to MYCN amplification in NB.11,48 However, TrkB expression 
is associated with unfavorable prognosis, has positive correlation with MYCN 
amplification, and is present in approximately more than half of high-risk 
neuroblastoma cases.49 Brain derived neurotrophic factor (BDNF) is a ligand that 
binds to TrkB receptors. Studies have reported that the activation of this receptor 
with BDNF can lead to drug-resistance, angiogenesis, and increased survival of 
tumor cells.50,51 Similar to TrkA, expression of TrkC appears to be favorable, is 
more common in low-risk disease, and has an inverse correlation with MYCN 
amplification.52  
 
PTPN11  
 About 3.4% of NB cases, particularly higher risk stages, contain mutations 
in the tyrosine-protein phosphatase non-receptor type 11 gene (PTPN11).46 
PTPN11 codes for the protein SHP-2, which is involved in the activation of the 
RAS-ERK and PI3K-AKT pathways.53 SHP-2 is also involved in EMT and the 
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modulation of focal adhesion kinases that keep the cell adhered to components 
in the extra cellular matrix.53 In fact, research shows that SHP-2 activation can 
promote metastasis and invasion of oral cancer.54 The sequencing of PTPN11 
from 13 different human cancers including neuroblastoma revealed 11 missense 
mutations, 5 of which caused the activation of SHP-2.53 A missense mutation, or 
point mutation, involves the substitution of a single nucleotide base and results in 
a codon that codes for a different amino acid. A change in an amino acid can 
lead to a change in protein structure and function. Synthetic inhibitors of SHP-2 
have demonstrated varying degrees of success when tested on different types of 
cancer. SHP099 and salicylic acid derivatives have been shown to inhibit cell 
proliferation and migration by inhibiting SHP-2, but this success seems to occur 
only when cells have intact, mutation-free, RAS-ERK pathways.55,56  
 
MYCN 
 MYCN amplification is considered to be the most important prognostic 
marker for high-risk neuroblastoma and is present in about 20% of cases.32 
MYCN is structurally related to another neural crest specifier c-myc, as two of 
their domains show a 78% and 83% similarity.57 Although both normal neural 
crest cells and neuroblastoma cells express the transcription factor MYCN, a 
study performed on mice demonstrated that MYCN levels progressively 
decreased in normal cells during development, but became consistently elevated 
in tumor cells.31 The over-expression of MYCN, with no other contributing factors 
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can cause neuroblastoma in mouse models.31 A study on the extent MYCN 
amplification in NB revealed that MYCN DNA could be amplified 20 to 140 fold in 
NB cells and that this amplification was more commonly seen in high risk patients 
with stage 3 or 4 cancer than those with stages 1 and 2. 58 MYCN plays a 
significant role in high risk neuroblastoma by promoting protein synthesis, 
proliferation, angiogenesis, metastasis, and immune system evasion through 
complex pathways.9 A summary of some of these cellular interactions can be 
seen in figure 6.  
 
Figure 6. Role of MYCN in Neuroblastoma. MYCN amplification can promote 
malignancy in a variety of ways.  
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 MYCN can inhibit cellular differentiation in numerous ways. Research has 
shown that MYCN can suppress the activity of alpha estrogen receptors (ERα) 
and NGF, which are both important for cellular differentiation.59 As noted on the 
Neuroblastoma Pathology Classification System, a less differentiated tumor is 
typically associated with a more malignant disease and unfavorable prognosis. 
MYCN can also block cellular differentiation by down-regulating CDKL5; although 
the exact actions of CDKL5 are not clear, an increase in this protein promotes 
cell cycle arrest and differentiation.60 In addition, knocking out MYCN expression 
along with other myc genes in neuroblastoma cell lines resulted in severely 
impaired pluripotency, self-renewal properties, and viability.61   
 Metastasis is yet another major concern in NB, as it has been reported to 
occur in approximately 50% of all cases.62 A research study on the regulation of 
metastasis found that the micro-RNA miR-9 was up-regulated in cancer cells and 
that increased levels correlated with increased metastasis.63 Typically, micro-
RNAs (miRNAs) are able to decrease post-transcriptional expression of specific 
proteins by binding to the protein’s own messenger RNA (mRNA) and 
destabilizing it. Ma et al found that miR-9 targeted the mRNA of the cell-to-cell 
adhesion molecule E-cadherin (CDH1), thereby increasing motility and promoting 
metastasis.63 Previous studies have shown that decreased E-cadherin levels can 
lead to increased expression of vascular endothelial growth factor (VEGF) via β-
catenin dependent pathways.64 Ma et al ultimately determined that miR-9 was 
activated by MYCN and that levels of miR-9 correlated with MYCN 
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amplification.63 This is a mechanism that still needs to be studied specifically in 
neuroblastoma cell lines, as the researchers used breast cancer cells for their 
analyses.  
 Much of the research being conducted demonstrates that there is an 
intricate relationship between MYCN amplification and the various ALK 
pathways. One major finding was that ALK signaling promoted the transcription 
of MYCN in both neuroblastoma and wild-type cells.65 This suggests that patients 
whose tumor cells express activating mutations of the ALK gene may also 
experience significant MYCN amplification and exhibit an aggressive form of 
cancer. Indeed, George et al, found that in a sample of 94 tumors with MYCN 
amplification, 15% also exhibited ALK amplification.34 The study also found that 
ALK amplification could not be detected in the 51 tumors that did not 
demonstrate MYCN amplification.34  
 Recent studies indicate that there is more than one mechanism by which 
ALK can promote MYCN expression. The PI3K-AKT pathway in particular has 
drawn much attention, as it appears to be the pathway most heavily associated 
with MYCN amplification and viability.  A study performed by Berry et al on a 
mouse model of neuroblastoma proposed that the ALK-PI3K-AKT pathway 
increases the oncogenic effects of MYCN protein by promoting its stabilization.66 
They demonstrated that P13K inactivates glycogen synthase kinase 3β (GSK3β), 
which can phosphorylate and deactivate MYCN; phosphorylated MYCN then 
becomes a target for ubiquination and degradation.66 GSK3β essentially acts as 
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an inhibitor of MYCN, but the continued activation of the ALK-PI3K pathway 
down-regulates this inhibitor and contributes to MYCN viability in the cell. 
Furthermore, a 2018 study by Claeys et al. found that PI3K signaling positively 
regulates MYCN by suppressing the expression of HMG-box transcription factor 
1 (HBP1).67 HBP1 has been shown to act as a negative regulator of MYCN.68 
Claeys et al also reported that MYCN itself could indirectly repress HBP1 levels, 
as it up-regulates a miRNA cluster known as miR-17~92, which targets HBP1 
mRNA.67  
 
WNT  
 WNT signaling functions through various frizzled (FZ) type receptors and 
regulates important cellular functions such as differentiation, migration, and cell 
polarity (figure 5).69 The structure of FZ receptors is similar to that of G-protein 
coupled receptors, as they also contain seven transmembrane domains. WNT 
glycoproteins are bound to the N terminal of FZ receptors and, once activated, 
can transduce a signal involving numerous downstream proteins. There are three 
main WNT signaling pathways, one being β-catenin dependent (also referred to 
as canonical) and two that are β-catenin independent, which include the planar-
cell-polarity (PCP) and the WNT-Ca2+ pathways. Comparatively, more research 
has been done on the role of tyrosine kinase pathways and MYCN in 
neuroblastoma than that of WNT signaling pathways.  
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 The different WNT signaling pathways may play distinct roles in NB 
pathogenesis. For instance, high risk human NB samples have been reported to 
have decreased levels of WNT5A, which is considered to be a part of the β-
catenin independent pathway.70 On the other hand, Dyberg et al confirmed that 
low-risk neuroblastoma was associated with decreased activity of the β-catenin 
dependent pathway.71  Dyberg et al also found that low risk neuroblastoma had 
increased levels of the PCP pathway components VANGL2 and PRICKLE1.71 It 
has been previously demonstrated that PRICKLE1 is an inhibitor of the β-catenin 
canonical pathway.72 The findings of these studies ultimately support the idea 
that the β-catenin independent pathways correlate with a favorable prognosis, 
while also proposing that the β-catenin dependent pathways may potentiate the 
disease. Although the role of the β-catenin dependent pathway is still not 
completely understood, research indicates that one of the receptors through 
which it operates (FZD1) may mediate the expression of a multidrug-resistant 
protein (MDR1) that causes treatment resistance in tumor cells.73 It is unknown 
whether or not MYCN interacts with WNT signaling as it does with ALK.  
 
ARID1A and ARID1B 
 A study by Sausen et al sequenced the genome of 71 NB tumors and 
found that 11% of the sample contained chromosomal deletions and alterations 
of ARID1A and ARID1B genes.74 ARID1A and ARID1B code for SWI/SNF 
proteins involved in chromatin remodeling, a process that alters how tightly DNA 
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is packaged and regulates gene expression.75,76  SWI/SNF proteins may also act 
as tumor suppressors and are involved in the regulation of cellular growth, 
division, maturation, DNA replication, and repair.75,76  A recent study by Kelso et 
al showed that the deletion of ARID1A and ARID1B was highly associated with 
changes in gene expression, particularly genes that coded for signaling 
intermediates in cellular growth and adhesion.77 The exact effects of ARID1A and 
ARID1B deletions in NB are not clear, but studies on liver cancer showed that 
ARID1A deletions promote progression and metastasis.78,79  
 
ATRX 
 ATRX loss of function mutations were found in 9.6% of patients in a study 
of 240 high-risk neuroblastoma cases, particularly in children over 18 months of 
age.46 ATRX mutations appear to be especially prominent in adolescent and 
adult patients.3  ATRX is an RNA helicase and the loss of its function leads to the 
lengthening of telomeres in tumor cells, although this effect seems to occur 
mainly in NB tumors that do not exhibit MYCN amplification.80,3 Telomeres are 
proteins that protect the ends of chromosomes from deterioration. The length of 
telomere segments usually decreases as cells continue to replicate. Typically, 
when telomeres become too short, cells lose their ability to replicate and begin to 
senesce. Thus, an increase in telomere length may increase the longevity of 
tumor cells as well as their replicative capability. Nonetheless, more research is 
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needed to determine the role of ATRX mutations in neuroblastoma and how they 
can lead to telomere lengthening.  
 
Neuritogenesis Genes 
Neuritogenesis is a process by which neurites (axons or dendrites) form. It is a 
complex signaling process that involves the GTPases Rho and Rac.81  Molenaar 
et al discovered that several proteins and regulators in the neuritogenesis 
pathway had undergone mutations in neuroblastoma, particularly in aggressive 
stage 3 or 4 tumors.82 Some of the mutated genes (PTPRD, ODZ2, ODZ3, 
CSMD1) are associated with neurite formation, while others (TIAM1, DLC1, 
ARHGAP10) function as Rac/Rho regulators.82 A 2017 study by Dyberg et al 
suggested that the mutations may involve the activation of downstream Rho 
associated kinases (ROCKs).83 In fact, the study demonstrated that increased 
expression of ROCK2 is linked to poor outcomes in NB and the inhibition of it can 
suppress tumor growth and promote MYCN degradation.84  
 
 
CHROMOSOMAL INSTABILITY  
 
 In addition to MYCN and ALK amplifications, there are other chromosomal 
abnormalities associated with NB, these include hyperploidy, chromothripsis, the 
deletion of chromosome arms 1p, 3p, 4p, and 11q, as well as the gain of 
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chromosome arm 17q.85 About one-third of tumors are diploid, while two-thirds 
are hyperploid.86 A human cell normally contains 23 pairs of chromosomes. A cell 
is considered hyperploid when it contains one or more chromosomes in excess. 
Tumor ploidy is an important prognostic marker in neuroblastoma, especially 
because infants with hyperploid tumors have increased survival rates.2,14 A study 
performed by Buckley et al. summarized the chromosomal aberrations that could 
be found in the neuroblastoma cell genome (figure 7).87 The researchers also 
calculated the frequency of MYCN and ALK amplifications, both of which appear 
on chromosome 2 (location 2p24.1 for MYCN and 2p23.1 for ALK).87 Figure 8 
depicts the risk level associated with these chromosomal alterations.  
 
 
Figure 7. Frequency of Segmental Chromosome Alterations. There are 
multiple additions (green) or deletions (red) of chromosome segments in 
neuroblastoma. Frequency of MYCN and ALK amplification is depicted by the 
blue line on chromosome 2. Figure taken from Buckley et al.87  
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Figure 8. Associated Risk Level for Tumors with Differing MYCN Status, 
Ploidy, and Chromosome Alterations. MNA represents MYCN amplification. 
Segmental or structural aberrations appear to play a role in disease 
aggressiveness but MYCN amplification remains the most important predictor. 
Taken from Ambros et al.88 
 
 
Loss of 11q Alleles 
 The loss of 11q can be relatively common in neuroblastoma, occurring in 
about 44% of sporadic cases and associated with increased malignancy.89 
Interestingly, loss of 11q is inversely correlated with MYCN amplification.87 Still, it 
is essential to find how the loss of alleles in this location can lead to 
tumorigenesis. Several of the 11q genes that may play a role in pathogenesis 
have already been identified and are currently being studied, including H2AX, 
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CADM1, ATM, PHOX2A, and SDHD.90 H2AX, for instance, codes for a histone 
protein. Histone proteins play an important role in the packaging of DNA and are 
involved in processes like transcription, replication, and the maintenance of 
chromosome stability.91  The loss of one H2AX allele can lead to chromosomal 
instability and increased risk of developing cancer.92 Furthermore, decreased 
expression of CADM1, cell adhesion molecule 1, has also been associated with a 
poor prognosis in several types of cancers, particularly those that are invasive 
and undergo metastasis.93,94 When neuroblastoma cells were made to over-
express CADM1, a decrease in proliferation was observed in-vitro.95 Another 
study focused on the role of ataxia-telangiectasia mutated (ATM) gene and found 
that haploinsufficiency of the ATM gene, which functions as a cell cycle 
checkpoint kinase and tumor suppressor, is also linked to lower cancer survival 
rates.96 The gene PHOX2A has been identified as a transcription factor that 
promotes noradrenergic neuronal differentiation during embryological 
development.90 It is regulated by a homologous molecule, PHOX2B (located on 
chromosome 4) and known for its association with familial neuroblastoma as well 
as its role as a neural crest developmental regulator.90 Microarray analysis 
revealed that there was decreased expression of PHOX2A in unfavorable tumor 
cells, though it is still not understood how lower levels of this transcription factor 
lead to pathogenesis.97    
 Finally, the tumor suppressor gene SDHD (located on 11q23) was also 
considered a potential candidate for neuroblastoma tumorigenesis because a 
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mutation of this gene had been linked to the onset of paraganglioma.98 A study 
performed by De Preeter et al, confirmed lower SDHD expression in cells with 
loss of the 11q allele.99 However, no evidence for SDHD involvement in NB 
pathogenesis was found, as they did not see signs of increased methylation or 
significant mutations of the gene in neuroblastoma cell lines.99 Thus, the 
researchers suggested that a haploinsufficient mechanism be considered for 
possible cause of disease.  
 
Gain of 17q Alleles 
 One of the most common genetic aberrations associated with advanced or 
aggressive neuroblastoma is the gain of 17q, which occurs in approximately 70% 
of cases and involves translocations of regions 1p and 11p, among others.85 The 
17q region that is gained contains about 18 genes, some of which are part of the 
ABCA ATP-binding transporter family that is known for causing drug resistance in 
tumors.87,100 Somatostatin receptor 2 (SSTR2) and the neural crest specifier 
SOX9 are also located in the 17q region.87 However, SSTR expression does not 
appear to be involved in tumorigenesis. Some studies have demonstrated that 
expressions of SSTR-1, 2, 3, and 4 were significantly higher in NB of favorable 
prognosis than in the unfavorable group.101,102  Somatostatin, the ligand for 
SSTR, usually has an inhibitory effect on hormonal pathways, secretion, and 
cellular growth.103 The contradictory outcomes for 17q addition and SSTR 
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expression shows the incredible complexity of neuroblastoma tumors and 
highlights the need for further research.  
 The transcription factor and neural crest specifier SOX9 has a role in 
maintaining stem cell phenotype, restricting cell lineage,104 and contributes 
towards epithelial mesenchymal transition as well as delamination.29 Like SSTR, 
the role that SOX9 may play in NB tumorigenesis is unclear, as it has exhibited 
contradicting properties in different types of cancer. Increased expression of 
SOX9 in colorectal cancer promotes proliferation.104 In contrast, SOX9 appears 
to behave as a tumor suppressor in some types of melanoma,104 a cancer that 
involves another neural crest derived cell, the melanocyte.  
 There is disagreement in the scientific community regarding the use of a 
gain in 17q as a prognostic factor for overall survival (OS) and event-free survival 
(EFS). While several studies indicate that gain of 17q is an independent predictor 
of a poor prognosis,105,106,107 other studies stated that 17q gain was not predictive 
of outcome in the absence of MYCN amplification or 11q deletion.86,108 
Nonetheless, almost all tumors that show MYCN amplification also exhibit 17q 
gain,105 perhaps suggesting a connection between the two prognostic factors. 
With this in mind, Godfried et al decided to study the downstream pathway of 
MYCN and determine if any genes on 17q were involved in the signal 
transduction.109 His group identified the 17q genes nm23-H1 and nm23-H2 as 
being potential players in the MYCN pathway, as they were expressed 6 to 10 
times more in MYCN+ neuroblastoma cells than those cells that did not have 
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MYCN amplification. The study hypothesized that the nm23 genes played a role 
in the malignancy of unfavorable neuroblastoma, though more extensive 
research is needed to understand the complete mechanism.  
 
Chromothripsis 
 The genome sequencing study by Molenaar et al revealed that NB tumors 
with poor prognoses may exhibit chromothripsis,82 a phenomenon discovered in 
2011110 characterized by a massive genomic rearrangement occurring in a single 
event. Chromothripsis appears to be associated with MYCN amplification and the 
loss of heterozygousity of chromosome segment 1b.82 The mechanism by which 
chromothripsis occurs is not known, but studies suggest it is a result of localized 
shattering of DNA and double stranded breaks.111 Molenaar et al suggested that 
chromothripsis may also occur from mutations in the fanconi signaling pathway, 
as the majority of NB cases that exhibited this phenomenon had inactivating 
mutations on fanconi-associated nuclease 1 (FAN1) and fanconi anemia 
complementation group M (FANCM).82 In addition to NB, evidence of 
chromothripsis has been found in several different cancers,112 including, but not 
limited to, acute lymphoblastic leukemia,113 invasive bladder carcinoma,114 
glioblastoma115 and osteosarcoma.110  
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REGRESSION MECHANISM 
 
 Neuroblastoma is a complex and heterogeneous disease, as it can show 
large variation in clinical behavior ranging from highly aggressive and malignant 
tumors to tumors that regress spontaneously without any kind of treatment and 
eventually turn into a benign form of ganglioneuroma. Understanding the 
mechanism of regression and spontaneous differentiation is just as important as 
understanding pathogenesis, since the mechanisms can potentially contribute to 
the development of new therapeutic drugs that will promote natural regression. 
Like many other mechanisms in neuroblastoma, the mechanism for spontaneous 
regression is not certain but several research studies have proposed pathways 
based on gathered evidence.116,117,118  
 Much of the research on the process of regression has focused on stage 
4s NB tumors because it is most commonly observed in this stage.23 TrkA has 
been identified as being a key player in the differentiation mechanism as there is 
increased TrkA expression in tumors with favorable prognosis.48,11 A 1997 study 
by Nakagawara and Brodeur demonstrated that when cells obtained from stage 
4s neuroblastomas were cultured and exposed to exogenous NGF (a TrkA 
ligand), the cells survived and were able to differentiate completely, thereby 
exhibiting a similarity to neuroblastomas that differentiated spontaneously into a 
benign, and more mature ganglioneuroma.10 The study also showed that a lack 
of exogenous NGF caused cell death, mimicking the tumor regression process 
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that is observed in some patients.10 Overall, these studies suggest that finding 
novel ways to up-regulate TrkA in NB tumor cells may be beneficial for patient 
survival.  
 Normally, apoptosis, a form of programmed cell death, is controlled by 
enzymes known as caspases.119 However, an electron microscope analysis of 
neuroblastoma regression showed that the cells were not dying via caspase 
regulated apoptosis, but rather via autophagy, another form of regulated cell 
death.120 Interestingly, the expression of Ras, an oncogene that participates in 
MAPK signaling, has been associated with a favorable prognosis121 and can 
reportedly trigger cell death through a caspase-independent pathway.122 
Kitanaka et al tested this theory specifically on neuroblastoma cell lines and 
confirmed that high levels of RAS were associated with the caspase-independent 
programmed death of cultured tumor cells.123 This is certainly a surprising 
observation, as the RAS-MAPK signaling cascade appears to be involved in 
tumorigenesis.45 More research is needed to understand the elusive role of RAS 
and its potential involvement in NB regression.  
 Several genetic factors may be linked to the spontaneous regression of 
neuroblastoma. Gene regulating factors such as promoter methylation as well as 
histone and chromatin modifications may be involved in the regression of 
tumors.8 Another genetic factor that has been suggested as a possible cause for 
spontaneous regression is a decrease in telomerase. Reportedly, stage 4s 
tumors exhibit lower levels of telomerase when compared to the more aggressive 
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types of neuroblastoma.124,125 A few factors are thought to play a role in the 
inhibition of regression, including MYCN amplification, the loss of chromosome 
segment 1p, and the gain of segment 17q.126  
 An additional mechanism of regression may be the targeting of 
neuroblastoma cells by the body’s immune system. Paraneoplastic opsoclonus is 
a condition characterized by the presence of anti-neuronal antibodies.127  About 
2% to 3% of children with neuroblastoma are also diagnosed with paraneoplastic 
opsoclonus128 and  typically have a high chance of survival.129 Another important 
observation was that high-risk tumors had decreased expression of human 
leukocyte antigen (HLA) class I, while favorable 4s tumors expressed normal 
levels of it.8,130,131 HLA class I molecules work to aid the body’s immune system 
in distinguishing endogenous proteins from those that may come from outside 
sources like an invading virus or bacteria. Taking into account these 
immunological studies, finding ways to up-regulate HLA class I molecules as well 
as anti-neuronal antibodies may prove to be a valid method of treating 
neuroblastoma.    
 
    CURRENT TREATMENT AND OUTCOMES  
 
Current Treatment  
 Patients diagnosed with NB receive various forms of treatment ranging 
from resection of the tumor, radiation, chemotherapy, Iodine 131-MIBG therapy, 
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and targeted therapy such as Trk inhibitors.5 Treatment varies depending on the 
stage and risk of the cancer, with children in low and intermediate risk groups 
which are comprised of non-MYCN tumors and 4S infants with or without 
metastasis, having generally good prognoses. Usually these patients are 
observed without implementing therapy or they may be offered low dose 
chemotherapy and resection.17  
 High risk patients typically receive a treatment plan with four distinct 
phases: induction chemotherapy, local control, consolidation, and maintenance.17 
After induction chemotherapy, local control involves resection of the tumor along 
with radiation to prevent local recurrence of the cancer.17 The consolidation 
phase aims to remove any remaining disease. It typically involves chemotherapy 
with autologous bone marrow transplantation, in which the patient’s own blood 
forming stem cells are drawn, frozen, stored, and returned to the patient when 
they have finished chemotherapy and radiation.17 In consolidation therapy, the 
patient may receive medications like retinoic acid, which has been shown to 
suppress tumor growth and promote differentiation in NB cell lines.132,133 Matthay 
et al. showed that autologous transplantation of bone marrow improved survival 
in children with high-risk NB.134 The study also reported that administering 
retinoic acid after chemotherapy and transplantation reduced the risk of cancer 
recurrence. However, a more recent study indicates that administration of retinoic 
acid after stem cell transplantation is inefficient in the treatment of high risk 
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NB.135 More research is needed to measure the efficacy of using retinoic acid as 
part of standard consolidation treatment. 
 
Outcomes 
 Event free survival (EFS) and overall survival (OS) rates vary relative to the 
patient’s risk group. A summary of survival rates based on risk classification is 
shown in figure 9. The National Cancer Institute defines EFS as the amount of 
time that a patient remains free of complications related to the cancer after 
treatment has ended.5 These complications can refer to the return of cancer or 
any of its associated symptoms or complications of treatment. OS rate refers to 
the percent of people in a study who are still alive after diagnosis or treatment of 
their disease.5 OS rates have vastly increased since the 1990s as research on 
neuroblastoma therapies and the understanding of disease mechanisms 
continues to improve (figure 10).136  
 
 
 
	  38 
 
Figure 9. Overall and Event-free survival for Different Genomic Groups of 
Neuroblastoma. Figure is based on sample of 90 patients. Group 1 (n=19) 
refers to no chromosomal alterations or exclusive to numerical chromosomal 
alterations. Group 2 (n=9) is for structural chromosomal alterations, excluding 
MYCN amplification. Group 3 (n=44) is for both numerical and structural 
alterations without MYCN amplification. Group 4 (n=10) is for structural 
alterations and MYCN amplification. Finally, group 5 (n=8) represents structural 
and numerical alterations as well as MYCN amplification. Figure taken from 
Oberthuer et al.137 
 
	  39 
 
Figure 10. Improvement of Overall Survival of Neuroblastoma between 1990 
and 2010. Survival probability has increased over the years as research 
continues to evolve. Taken from Pinto et al based on data collected by the 
Children’s Oncology Group.137    
 
 
     TREATMENT RESEARCH 
 
Immunotherapy  
 Immunotherapy is one of the main focuses of neuroblastoma research, 
attempting to find a way to enhance the body’s own immune system to target 
cancer cells. One of the therapies developed by Yu et al is a combination therapy 
with an anti-GD2 monoclonal antibody named ch14.18 (also known as 
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Dinutuximab), along with granulocyte-macrophage colony-stimulating-factor (GM-
CSF), interleukin-2 (IL-2), and retinoic acid.139 GD2 is a cell surface 
disialoganglioside that is almost exclusively  expressed in NB tumor cells.138,139 
Melanocytes and neurons also express GD2,140 although the latter are protected 
by the blood brain barrier and may not be exposed to immunotherapy agents.141 
The trial completed phase III in 2012 and showed a significant increase in EFS 
and OS. Patients receiving immunotherapy had an estimated EFS of 66±5% 
compared to 46±5% for standard therapy. Similarly, immunotherapy patients had 
an estimated OS of 86±4%, while patients in the standard therapy group had an 
OS of 75±5%. Anti-GD2 monoclonal antibodies have since become an essential 
component of high risk NB treatment.142 Nonetheless, the treatment has several 
side effects including abdominal pain, hypersensitivity reactions, and capillary 
leak syndrome.143 Yu et al reported that one patient died from complications of 
capillary leak syndrome caused by an accidental overdose of IL-2.139 Given the 
high dose toxicity of IL-2, a similar phase III clinical trial is being conducted 
comparing the outcomes of this combination therapy with and without IL-2 after 
an autologous stem cell transplant is performed on the patient.144 Another 
currently active phase 1 trial is adding new genes to anti-GD2 white blood cells 
(GD2 T cells) in order to prolong their lifespan and increase their chances of 
killing NB tumor cells.145 In general, anti-GD2 immunotherapies have proven to 
be highly effective at targeting NB cells while doing minimal damage to healthy 
tissue, unlike highly toxic chemotherapeutic agents.146  
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Inhibition of MYCN 
 Efforts have been made to design a drug that can suppress or inhibit 
MYCN. The cell cycle regulators Aurora Kinase A (AURKA) and Aurora Kinase B 
(AURKB) have been shown to potentiate the effects of the MYCN oncogene. 
AURKA appears to play a role in the stabilization of MYCN,147 while AURKB has 
been identified as one of its transcriptional targets.148 Alisertib is a drug that has 
been designed to function as an AURKA inhibitor, but the drug showed low 
response rates when given to patients who had been diagnosed with solid 
tumors, including NB.149,150 Combining Alisertib with Irinotecan and 
Temozolomide produced a synergistic effect and an increased response rate of 
31.8%.151 Irinotecan acts as an inhibitor of  topoisomerase152, a protein needed 
for untangling DNA during replication, while Temozolomide is an alkylating agent 
that halts proliferation by adding an alkyl group to DNA and altering its 
structure.153 Like other chemotherapies, several patients in this combination 
study experienced neutropenia,151 a condition characterized by abnormally low 
levels of white blood cells known as neutrophils.  
 Researchers have tried to identify inhibitors that can target both AURKA 
and AURKB with the hopes of producing more favorable treatment results. Two 
inhibitors in this category are Tozasertib and CCT137690.154,155 Tozasertib led to 
cell cycle inhibition and induction of apoptosis.155 It has been shown, however, 
that expression of ABCB1 transporters confers resistance to Tozasertib but not to 
Alisertib.155 ABCB1 transporters transfer a variety of substrates across the cell 
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membrane and are known to cause resistance in the treatment of several  
cancers, including breast and ovarian cancer.156  In addition, pre-clinical trial 
testing of CCT137690 on MYCN amplified cell lines led to a decrease in 
proliferation and MYCN expression.154 Side effects of Aurora kinase inhibitors 
include neutropenia, gastrointestinal toxicity, hypertension, and stomatitis. 157  
 Other researchers have studied the MYCN signaling pathway to identify 
and target its mediators. A histone chaperone called FAcilitates Chromatin 
Transcription (FACT) has been identified as one of these MYCN mediators and 
was found to be involved in a forward feedback loop that contributed to the 
increased expression of both MYCN and FACT itself.158 FACT inhibition was 
achieved using Curaxin, or CBL0137, which worked cooperatively with 
chemotherapy agents by preventing the repair of damaged DNA caused by the 
exposure to the chemotherapy drugs.158  
 
Inhibition of ALK 
 The tyrosine kinase receptor ALK is being targeted by two inhibiting drugs, 
Crizotinib and Ceritinib, with Certinib being 20 times more powerful than the 
former.159 Although the drugs showed positive results in patients with other types 
of cancers, they were unable to produce optimal results in neuroblastoma 
patients, where neuroblastoma tumors appeared to be resistant because of 
acquired mutations in the ALK gene.159 Shen et al tested the effectiveness of a 
combination therapy consisting of Crizotinib and an inhibitor of histone 
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deacetylase 8 (HDAC8) that is lethal to both HDAC8 and ALK.160 HDAC8 is also 
an indicator of unfavorable prognosis in patients with neuroblastoma and its 
inhibition has been shown to promote differentiation.161 The combination therapy 
killed neuroblastoma cells with wild type ALK, amplified ALK, and even those that 
had activating ALK mutations. The sensitization of resistant models was also 
achieved. The most common side effects from Crizotinib treatment include visual 
effects (appearance of flashing or shimmering lights) and liver enzyme 
abnormalities.162 A more recent study on combination therapy blocked both ALK 
and MDM2, a ubiquitin ligase that targets the tumor suppressor protein p53 for 
degradation.159 This study found that blocking ALK and MDM2 simultaneously 
could potentially overcome Crizotinib resistance as well. Admittedly, more 
research is required on these combination therapies to prove their effectiveness 
in neuroblastoma patients.  
 
Promoting Differentiation 
 Retinoic acid promotes neuronal differentiation, but its lack of success in 
the treatment of high risk NB has driven researchers to find more effective 
combination therapies. A recent study by Westerlund et al observed the effects of 
5-Aza-deoxycytidine (AZA) and retinoic acid on NB cell lines.163 They found that 
AZA sensitizes the cells for retinoic acid treatment, consequently leading to 
decreased proliferation and increased differentiation. Tumors that were treated 
with AZA and retinoic acid were about 4 times smaller than those in the negative 
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control group, which were treated with DMSO.  Another study by Rettig et al 
combined retinoic acid with HDAC8 inhibitors, which also resulted in increased 
differentiation and reduced levels of MYCN expression.164 Experiments on mice 
revealed that exceeding the tolerable dose of 10 mg/kg per day led to severe 
abdominal swelling.  
 
DISCUSSION 
 
 Neuroblastoma, like many other cancers, is a complex disease that 
involves various cellular mechanisms. MYCN amplification, ALK mutations, and 
structural and numerical alterations of the genome have been linked to the onset 
of this disease. Recent sequencing studies have identified even more genetic 
factors that drive NB including the occurrence of chromothripsis and changes in 
PTPN11, ATRX, ARID1A, ARID1B, and neuritogenesis genes. The discovery of 
these factors has helped researchers gain a better understanding of the disease 
pathway, but the exact mechanisms of action are still not entirely understood. 
Nonetheless, there have been improvements in the identification of high-risk 
patients and the development of therapies. Despite this progress in treatment, 
however, resistance to therapy, low efficacy, and toxicity have been some of the 
biggest barriers in the treatment of high-risk patients, who continue to exhibit 
survival rates that are lower than 50%.165 Problems relating to drug resistance 
are being addressed by attempting several combination therapies that may 
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incorporate chemotherapy and immunotherapy drugs in order to target more than 
one component of the disease pathway. Some currently active clinical trials are 
testing an experimental drug Hu3F8 (an anti GD2-monoclonal antibody) in 
combination with other drugs including Irinotican, Temozolomide, and GM-
CSF.166,167,168 Other active immunotherapy trials are focusing on the combination 
of antibodies and natural killer T cells to target GD2.169 Some researchers are 
also incorporating the use of retinoic acid and immunotherapy to simultaneously 
kill cancer cells and promote differentiation.170 Evidently, immunotherapy testing 
has been a major focus for current trials because NB tumor cells, given their 
neuroectoderm origin, express unique biomarkers that can be used as potential 
targets. Thus, immunotherapy may prove to be less toxic than chemotherapy 
drugs.  
 The role of research and clinical trials is incredibly important in the 
treatment of patients. It was previously reported that approximately 76% of NB 
patients were enrolled in an active clinical trial.165 Survival rates for 
neuroblastoma have consistently increased in the past decades and 
improvements may be seen in the coming years as current trials reach 
completion. Nonetheless, it is essential to continue exploring pathogenesis and 
regression mechanisms to further understand NB and keep improving treatment 
strategies and patient outcomes. Future advances in NB research could lead to 
the development of more detailed staging and risk analysis systems that will help 
healthcare professionals determine the best line of treatment for high-risk 
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patients and reduce treatment of low-risk patients who are likely to experience 
spontaneous regression.  
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